This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotechrss

$40 Billion Takeover Has Big Pharma Giddy

Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?

04/28/16 - 01:30 PM EDT

Sarepta Can Win Speedy FDA Drug Approval

  • Tickers in this article:
  • SRPT

Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.

04/28/16 - 10:17 AM EDT

$40 Billion Takeover Has Big Pharma Giddy

$40 Billion Takeover Has Big Pharma Giddy

Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?

04/28/16 - 01:30 PM EDT

Sarepta Can Win Speedy FDA Drug Approval

Sarepta Can Win Speedy FDA Drug Approval

  • Tickers in this article:
  • SRPT

Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.

04/28/16 - 10:17 AM EDT

Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

  • Tickers in this article:
  • VRTX

Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.

04/27/16 - 05:03 PM EDT

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind and Its CEO Fail Simple Financial Literacy Test

  • Tickers in this article:
  • MNKD
  • SNY

MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.

04/27/16 - 07:35 AM EDT

An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting

An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting

  • Tickers in this article:
  • SRPT

The FDA advisory panel review of Sarepta's DMD drug eteplirsen will be surprising, controversial, volatile, dramatic, newsworthy and memorable.

04/24/16 - 12:46 PM EDT

4 Biotech Stocks You Should Be Watching Right Now

4 Biotech Stocks You Should Be Watching Right Now

Biotech stocks are dominating the strong stock charts on our radar.

04/22/16 - 12:55 PM EDT

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

04/22/16 - 08:31 AM EDT

FDA Still Negative on Sarepta's DMD Drug; Stock Price Sinks

FDA Still Negative on Sarepta's DMD Drug; Stock Price Sinks

  • Tickers in this article:
  • SRPT

The news was still negative for eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics.

04/21/16 - 09:58 AM EDT

Jim Cramer -- Gilead Sciences Needs to Do a Deal

Jim Cramer -- Gilead Sciences Needs to Do a Deal

The drug discovery company's organic growth isn't enough to continually fuel growth, Cramer says.

04/20/16 - 01:33 PM EDT

Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money

Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money

Efforts by insurers to negotiate higher discounts or rebates on specialty pharmaceutical products aren't keeping pace with the price increases pushed through by drug and biotech companies, an analyst says.

04/20/16 - 10:10 AM EDT

Bluebird Bio Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease

Bluebird Bio Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease

Bluebird is trying to use a gene therapy to correct the rare and fatal genetic defect found in boys with CALD.

04/20/16 - 08:31 AM EDT

Experts Take Solace in Citigroup's Capital Structure

Experts Take Solace in Citigroup's Capital Structure

Analysts are feeling optimistic about the New York mega-bank.

04/18/16 - 03:50 PM EDT

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Markets

Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%
Top Rated Stocks Top Rated Funds Top Rated ETFs